Research concludes that postmenopausal osteoporotic women taking bisphosphonate
drugs exhibited better and increased bone health compared to those not taking bisphosphonates
are derived from naturally occurring inorganic pyrophosphate (PPi).
The Food and Drug Administration (FDA) recommends that patients use bisphosphonates
for three to five years, after which they should be reassessed by their clinician.
In addition to the promising signal of a preventive effect for bisphosphonates
, her analysis of Osteoarthritis Initiative data yielded two other major findings: Changes over time in the MRI-based three-dimensional bone shape of the knee constitute a novel structural imaging biomarker that appears to be of value in monitoring patients with OA or at high risk for the joint disease, and bisphosphonate-induced suppression of bone turnover had no adverse long-term impact on osteoarthritis risk.
and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.
It appears that patients and perhaps some clinicians have the mistaken impression that bisphosphonates
frequently cause serious adverse effects.
Bandeira, "Atypical femoral fractures during prolonged use of bisphosphonates
: short-term responses to strontium ranelate and teriparatide," Journal of Clinical Endocrinology & Metabolism, vol.
The guidelines emphasize the need for reassessment of fracture risks on a regular basis for all women being treated with bisphosphonates
BRONJ is the most seen complication (66%) due to bisphosphonates
The vast majority of atypical femur fractures are seen after long-term bisphosphonate
use, and many doctors now recommend a five-year limit for taking them, with a periodic assessment of whether the drug is still necessary.
Results showed that there were significant difference of second hip fracture (Pless than 0.05) and mortality (Pless than 0.05) between bisphosphonates
group and control group.
Cells were incubated with each of the four alkyl bisphosphonates
at a final concentration of 10 mM.